Acrigen Biosciences
PrivateLast Round
Seed
Sep 28, 2021
Total Funding Raised
$256,580
Company Overview
Acrigen Biosciences is a biotechnology company that develops precision gene editing systems using CRISPR-Cas nucleases and engineered anti-CRISPR proteins to improve the safety and efficacy of genetic therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Acrigen Biosciences Comparables
Compare Acrigen Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Acrobat Genomics | 79% | |
| Arbor Biotechnologies | 77% | |
| Alia Therapeutics | 76% |
Acrigen Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Sep 28, 2021 | ||||
| Grant | Dec 12, 2019 |
Acrigen Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Dolby Family Ventures | Seed |
| Berkeley Catalyst Fund | Seed |
| Alexandria Venture Investments | Seed |
| Red Tree Venture Capital | Seed |
| National Institute of General Medical Sciences | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 12, 2019
$257K grant awarded by National Institute of General Medical Sciences.
Acrigen Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Acrigen Biosciences's valuation, stock price, and market status.
Is Acrigen Biosciences a public or private company?
Acrigen Biosciences is a private company.
What is the current stock price of Acrigen Biosciences?
Acrigen Biosciences is a private company with no public stock price. No recent secondary market data is available.
How much is Acrigen Biosciences worth (valuation)?
Valuation information for Acrigen Biosciences is not publicly available.
Can I buy Acrigen Biosciences stock?
Acrigen Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Acrigen Biosciences's last funding round?
Acrigen Biosciences's most recent funding round was Seed on September 28, 2021.
Who are the main investors in Acrigen Biosciences?
Key investors in Acrigen Biosciences include Red Tree Venture Capital.
Will Acrigen Biosciences IPO soon?
No public IPO plans have been announced for Acrigen Biosciences.
How can I track Acrigen Biosciences secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Acrigen Biosciences's secondary market activity and sign up for updates.